Prognostic Factors of COVID19

Study of Clinical, Biological and Genetic Prognostic Factors of SARS-CoV-2 Infection in Patients Admitted in the Strasbourg University Hospitals

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04405726

Acronym

Covid-HUS

Enrollment

500

Registered

2020-05-28

Start date

2020-03-27

Completion date

2022-03-31

Last updated

2020-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2

Keywords

SARS-CoV-2, Covid-19, Prognostic factors, Genetic factors, T and B cell immune response

Brief summary

COVID-19 is an emerging disease, for which no specific treatment options are currently available. Since the end of February 2020, and due to a SARS-CoV-2 superspreading event (religious meeting), the Strasbourg University Hospital (HUS) had faced a sudden increase of the number of COVID-19-positive patients in serious condition requiring hospitalization. At the same time, many people develop only mild or moderate symptoms. To date, the prognostic factors for the course of SARS-CoV-2 infection are unknown. The primary purpose of the COVID-HUS protocol is to investigate viral and host-related factors to understand the pathophysiology of COVID infection and to open the way for new diagnostic, prognostic and therapeutic strategies against SARS CoV-2 . The secondary objectives are * Monitoring of viral replication of SARS-CoV-2 in the blood and respiratory tract in infected patients * Monitoring of the humoral and cellular response directed against SARS-CoV-2 * Identification of factors leading to significant and / or prolonged viral replication of SARS-CoV-2 in the blood or respiratory samples * Evaluation of the benefit of possible treatments implemented following the diagnosis of SARS-CoV-2 infection * Exploration of the B and T immune repertoire sequences targeting SARS-CoV-2 in infected patients * Typing of the HLA system in infected patients

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

1 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult and pediatric with suspicion or a confirmed SARS-CoV-2 infection * Patient who has signed a non-opposition form (or a form signed by a family member or a support person if the seriousness of the patient's condition and the emergency situation do not allow it) or who has given his oral agreement to the doctor

Exclusion criteria

* Patient's explicit refusal to participate * Subject deprived of liberty or subject to the protection of justice * Subject under guardianship or trusteeship

Design outcomes

Primary

Measure	Time frame
Clinical Presentation and Incidence of Covid-19 Infection in patients hospitalised in Strasbourg Hospital	From 1st March 2020 to 1st March 2021

Countries

France

Contacts

Primary ContactSamira FAFI-KREMER, PharmD, PhD

Samira.fafi-kremer@chru-strasbourg.fr33.3.69.55.14.38

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results